IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.

IceCure Medical’s next-generation cryoablation technology to receive European patent: Caesarea, Israel Monday, January 6, 2025, 13:00 Hrs [IST] IceCure Medical Ltd., a developer ...

The Boston Scientific Cardiac Cryoablation System using POLARx Cryoablation Balloon Catheters is indicated for the treatment of recurrent, symptomatic atrial fibrillation, which leads to irregular ...

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen ...

But the real allure, Huang and McArthur said, is cryoablation’s impact on the immune system. When the tumor freezes and thaws, the cancer cells crumble apart, exposing the immune system to ...

FDA Granted Regulatory Clearance for XSense™ Cryoablation System with CryoProbes: The next-generation XSense™ system is cleared for the same indications that our flagship ProSense® system is ...

The abstract titled "Cryoablation as a primary treatment for ... the Japan Patent Office for its invention titled 'Cryogenic System with Multiple Submerged Pumps'. IceCure Medical Ltd. (Nasdaq ...

Icecure Medical ( ) has issued an update. IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector t ...

FDA Granted Regulatory Clearance for XSense™ Cryoablation System with CryoProbes: The next-generation XSense™ system is cleared for the same indications that our flagship ProSense® system is ...

Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors. FDA decision on ...